International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 11 November 2023

Page No: 2865-2870

DOI: https://doi.org/10.47191/ijmscrs/v3-i11-61, Impact Factor: 6.597

McCune-Albright Syndrome: A Comprehensive Review of Pathophysiology, Clinical Manifestations, and Therapeutic Approaches

Aquino-Ruelas Lizeth[1], Kobayashi-Corona Jessica Aneet[2], Gálvez-Sánchez Benigno[3], Molinero-Cárdenas Andrea[4], Perez-Franco Nebi Nazaret[5], Armenta-Ayón Fátima Lucia[6]

[1,2,3,4,5,6] Universidad Autónoma de Guadalajara. Guadalajara, Jalisco, México.

ABSTRACT

McCune-Albright Syndrome (MAS) is a rare and complex disorder that primarily affects the bones, skin, and endocrine system. It is characterized by a mosaic pattern of somatic mutations in the GNAS gene, leading to constitutive activation of adenylate cyclase and excessive production of cyclic AMP (cAMP). This dysregulated cAMP signaling pathway results in a wide spectrum of clinical manifestations, including polyostotic fibrous dysplasia, café-au-lait skin pigmentation, and various endocrinopathies such as precocious puberty, hyperthyroidism, and hypercortisolism. This comprehensive review aims to provide an in-depth understanding of the pathophysiological mechanisms underlying MAS, a detailed exploration of the diverse clinical features, and a discussion of the current and emerging therapeutic strategies for managing this rare disorder. The article synthesizes research findings, clinical experiences, and genetic insights to shed light on the challenges faced by healthcare providers in diagnosing and treating patients with MAS.

KEYWORDS: McCune Albright, syndrome, disorder, endocrine.

ARTICLE DETAILS

Published On:
22 November 2023

Available on:
https://ijmscr.org/

INTRODUCTION

McCune-Albright Syndrome (MAS) stands as a unique and multifaceted condition that captivates the attention of clinicians, geneticists, and researchers alike. First described by Donovan James McCune and David H. Albright in 1937, MAS is characterized by a triad of clinical features: polyostotic fibrous dysplasia, café-au-lait skin pigmentation, and multiple endocrinopathies, most notably precocious puberty (1). This enigmatic syndrome is rooted in the somatic mosaic mutations of the GNAS gene, leading to constitutive activation of adenylate cyclase and the subsequent overproduction of cyclic AMP (cAMP) (2). The resulting dysregulation in cAMP signaling has far-reaching implications, affecting various organ systems and giving rise to a diverse range of clinical manifestations.1,2

The intricacies of MAS necessitate a holistic understanding, as patients may present with a plethora of symptoms, often requiring a multidisciplinary approach to diagnosis and management. In light of its rarity, with an estimated prevalence of one in 100,000 to one in 1,000,000, clinical expertise and comprehensive knowledge are essential (3). This review seeks to unravel the complexities of MAS, delving into its pathophysiological underpinnings, the intricate network of endocrine disturbances, and the evolving therapeutic modalities for managing this intricate disorder.1,2

In the following sections, we will embark on a journey through the molecular basis of MAS, exploring the genetics and signaling pathways that underlie its pathogenesis. We will also dissect the clinical manifestations of MAS, paying particular attention to the diverse endocrinopathies that often manifest and exploring the challenges of early diagnosis. Additionally, this article will present an overview of current therapeutic approaches and emerging strategies aimed at addressing the myriad complications associated with MAS.2,3

In summary, this review endeavors to provide a comprehensive and up-to-date resource for healthcare professionals and researchers alike, as we strive to gain a deeper understanding of McCune-Albright Syndrome and enhance our ability to provide effective care and management for individuals affected by this rare and challenging disorder.2,3

EPIDEMIOLOGY

McCune-Albright Syndrome (MAS), a rare and intriguing disorder of mosaic somatic mutations within the GNAS gene,

stands as an exceptional example of the interplay between genetics, clinical heterogeneity, and epidemiological intricacies. Understanding the epidemiological landscape of MAS is pivotal for clinicians, researchers, and healthcare policymakers as it provides essential insights into the prevalence, demographics, geographic distribution, and associated risk factors of this condition. This comprehensive discussion will delve into the epidemiology of MAS, shedding light on the current state of knowledge, knowledge gaps, and the implications for clinical practice and research.3,4

Prevalence and Incidence: MAS is a rare disorder, and its precise prevalence remains elusive. Studies have estimated the prevalence to be approximately one in 100,000 to one in 1,000,000 live births (1). Such a low prevalence emphasizes the rarity of this syndrome, making it a challenging diagnosis for clinicians. The incidence of MAS may not be readily quantifiable due to the mosaic nature of GNAS mutations, which can lead to variable clinical presentations even among affected individuals.3,4

Age of Onset and Gender Distribution: The age of onset of MAS can vary widely and depends on the clinical manifestations. Notably, many of the endocrinopathies associated with MAS, such as precocious puberty, may become evident in childhood, while other features, like polyostotic fibrous dysplasia, can develop at any age. Regarding gender distribution, MAS affects both males and females, with no pronounced sexual predilection. However, certain endocrinopathies, such as precocious puberty, may exhibit gender-specific differences in presentation and management.4,5

Geographic and Ethnic Variation: The epidemiological landscape of MAS also reveals some geographic and ethnic variations. While MAS has been reported worldwide, it may be underdiagnosed or underreported in some regions due to a lack of awareness among healthcare professionals. Variations in genetic susceptibility and environmental factors may contribute to differences in the prevalence and presentation of MAS among diverse populations. Research on these geographic and ethnic disparities is ongoing and may provide crucial insights into the genetic underpinnings of the syndrome.5,6

Associated Risk Factors: The etiology of MAS is primarily genetic, with mosaic mutations in the GNAS gene serving as the cornerstone of pathogenesis. Nevertheless, understanding potential genetic modifiers and environmental factors that influence the clinical expression of MAS remains an active area of research. Some individuals with MAS may harbor additional genetic variants that could impact the severity or diversity of clinical features.5,6

Challenges in Epidemiological Research: Epidemiological studies on MAS face several challenges. The rarity of the syndrome makes it difficult to assemble large cohorts for robust statistical analyses. Furthermore, the mosaic nature of GNAS mutations can result in varying clinical presentations within affected individuals, posing challenges for data collection and interpretation. Collaboration among institutions and countries is essential to gather comprehensive epidemiological data.5,6

In conclusion, unraveling the epidemiology of McCune-Albright Syndrome is an ongoing endeavor that offers valuable insights into the disease's rarity, demographic patterns, and potential regional variations. As our understanding of MAS deepens and more data are collected, it becomes increasingly important for healthcare providers, researchers, and policymakers to collaborate in addressing the challenges posed by this complex and multifaceted disorder. Such efforts are pivotal in improving diagnostic accuracy, patient care, and the development of tailored therapeutic strategies for individuals affected by MAS.6,7

CLINICAL MANIFESTATIONS

McCune-Albright Syndrome (MAS) is a rare and multifaceted disorder characterized by a diverse spectrum of clinical manifestations that affect multiple organ systems. These clinical features are a consequence of mosaic somatic mutations within the GNAS gene, leading to constitutive activation of adenylate cyclase, excessive cyclic adenosine monophosphate (cAMP) production, and ultimately, a wide array of phenotypic variations. Understanding the intricate clinical presentations of MAS is pivotal for clinicians and healthcare providers as it guides diagnosis, management, and patient care. This comprehensive discussion will delve into the clinical manifestations of MAS, encompassing skeletal, cutaneous, and endocrine abnormalities, while highlighting the challenges in diagnosis and management.6,7

Skeletal Manifestations: Polyostotic fibrous dysplasia is a hallmark skeletal manifestation of MAS, and it presents with a wide range of severity and distribution. Affected individuals exhibit areas of abnormal bone formation, resulting in deformities, fractures, and pain. This can involve various bones, including the skull, long bones, pelvis, and spine. Fibrous dysplasia may lead to an uneven limb length, spinal curvature, and craniofacial asymmetry.6,7

Cutaneous Manifestations: Café-au-lait spots are a distinctive cutaneous feature of MAS. These pigmented macules are characterized by their light to dark brown coloration, irregular borders, and often, a "coast of Maine" or "jagged" appearance. These spots frequently present in a segmental distribution and can vary in size and number.6,7

Endocrine Manifestations: MAS is renowned for its wide array of endocrine abnormalities, and these often constitute the primary clinical concern for affected individuals. Some of the key endocrine manifestations include:6,7

- *Precocious Puberty*: Precocious puberty, characterized by premature development of secondary sexual characteristics, is a frequent concern in MAS, primarily

in females. This can lead to early menarche and rapid skeletal maturation.6,7

- *Thyroid Dysfunction*: Thyroid involvement in MAS may manifest as hyperthyroidism, goiter, or autonomously functioning thyroid nodules.6,7
- *Growth Hormone Excess*: Excessive production of growth hormone may result in gigantism in children or acromegaly in adults.6,7
- *Cortisol Overproduction*: Hypercortisolism, often due to adrenal nodular hyperplasia, can lead to Cushing's syndrome.6,7
- *Gonadal Abnormalities*: Ovarian cysts and testicular lesions are potential manifestations in MAS.6,7
- *Parathyroid Dysfunction*: Abnormalities in parathyroid function can result in hypercalcemia and renal complications.6,7

Extraskeletal and Extracutaneous Manifestations: MAS can also involve other organ systems, including the liver, spleen, and pancreas. Gastrointestinal bleeding, hepatobiliary issues, and pancreatic lesions may be present in some cases, further adding to the clinical complexity.6,7

Challenges in Diagnosis and Management: The mosaic nature of GNAS mutations in MAS can result in variable clinical presentations among affected individuals, even within the same family. This variability often poses diagnostic challenges, as well as the need for a multidisciplinary approach to care. The management of MAS is tailored to the specific clinical manifestations present in each patient, encompassing surgical interventions, pharmacological treatments, and supportive care. Close monitoring and early intervention are crucial to addressing the diverse complications associated with MAS.8,9

In summary, the clinical manifestations of McCune-Albright Syndrome are a testament to the complexity and heterogeneity of this rare disorder. Recognizing and understanding the skeletal, cutaneous, and endocrine abnormalities, along with potential extraskeletal manifestations, is paramount for healthcare providers in order to offer timely diagnosis, effective management, and improved quality of life for individuals living with MAS. Future research and collaboration among healthcare professionals will further enhance our ability to address the intricacies of this challenging syndrome.8,9

DIAGNOSIS

McCune-Albright Syndrome (MAS) presents a diagnostic challenge to healthcare professionals due to its wide-ranging and heterogeneous clinical manifestations. The syndrome, characterized by mosaic somatic mutations in the GNAS gene and resultant endocrine, skeletal, and cutaneous abnormalities, requires a comprehensive and multidisciplinary approach to diagnosis. This in-depth discussion delves into the intricate diagnostic process for MAS, highlighting the essential components, the role of genetic testing, and the importance of differential diagnosis.8,9

Clinical Evaluation: The diagnostic journey for MAS typically commences with a thorough clinical evaluation. This includes a comprehensive medical history, physical examination, and the identification of characteristic clinical features. The presence of polyostotic fibrous dysplasia, café-au-lait spots, and endocrine abnormalities, such as precocious puberty or hyperthyroidism, can raise suspicion of MAS. However, the mosaic nature of GNAS mutations often results in a highly variable clinical presentation, necessitating a high index of clinical suspicion.8,9

Radiological Assessment: Radiological imaging plays a crucial role in the diagnostic process. Skeletal radiographs, computed tomography (CT) scans, and magnetic resonance imaging (MRI) are employed to assess the extent and severity of fibrous dysplasia. Characteristic findings on imaging may include ground-glass appearance, expansile lesions, and areas of increased radiodensity. Additionally, bone scintigraphy with technetium-99m can aid in identifying areas of increased metabolic activity.8,9

Hormonal and Laboratory Testing: Given the prominent endocrine manifestations associated with MAS, hormonal and laboratory testing is integral to the diagnostic process. Hormonal evaluation may include assessments of thyroid function, growth hormone levels, cortisol secretion, and sex hormone profiles. Hyperthyroidism, elevated growth hormone, or increased cortisol levels can serve as valuable diagnostic clues. Serum and urine markers, such as 24-hour urinary free cortisol and adrenocorticotropic hormone (ACTH) levels, can help in confirming the presence of Cushing's syndrome.8,9

Molecular Genetic Testing: A definitive diagnosis of MAS often necessitates molecular genetic testing. Genetic analysis of the GNAS gene, typically through next-generation sequencing techniques, is instrumental in identifying mosaic mutations that underlie the syndrome. Sanger sequencing and allele-specific PCR (polymerase chain reaction) can be employed to detect specific GNAS mutations, which may not be readily apparent in standard blood tests due to the mosaic nature of the mutations.8,9

Histopathological Evaluation: In cases where fibrous dysplasia is surgically excised, histopathological examination of the bone tissue can provide additional diagnostic confirmation. Characteristic histological features include the replacement of normal bone by fibrous tissue with irregularly shaped trabeculae and increased vascularity.8,9

Differential Diagnosis: The diagnostic process for MAS is further complicated by the necessity of distinguishing it from various other medical conditions that share some clinical features. For example, isolated fibrous dysplasia, multiple endocrine neoplasia syndromes, and other genetic or non-genetic causes of precocious puberty or endocrine

abnormalities must be considered in the differential diagnosis.8,9

In conclusion, diagnosing McCune-Albright Syndrome is a multifaceted challenge that requires the integration of clinical evaluation, radiological imaging, hormonal assessment, genetic testing, and histopathological examination. The complexity of MAS, characterized by its mosaic GNAS mutations and the variable clinical presentation among affected individuals, underscores the importance of a multidisciplinary approach. Accurate and early diagnosis is essential for providing appropriate care and management to individuals with MAS, ultimately improving their quality of life and clinical outcomes. Future research and advancements in genetic testing are likely to further refine the diagnostic process for this rare and intricate syndrome.10

TREATMENT

McCune-Albright Syndrome (MAS), a complex and rare disorder characterized by mosaic somatic mutations in the GNAS gene, presents a multitude of clinical manifestations affecting the skeletal, cutaneous, and endocrine systems. The management of MAS demands a nuanced, multidisciplinary approach that addresses the diverse clinical features while aiming to improve the quality of life for affected individuals. This in-depth discussion explores the therapeutic strategies employed in the management of MAS, encompassing surgical, pharmacological, and supportive interventions, and highlights the evolving landscape of potential targeted therapies.11,12

Surgical Interventions:

Skeletal Management: The treatment of polyostotic fibrous dysplasia, a cardinal feature of MAS, may necessitate surgical intervention. Surgical procedures include curettage and bone grafting, which aim to stabilize fractures, alleviate pain, and correct deformities. In severe cases, osteotomies and joint replacements may be required to improve mobility and function.11,12

Endocrine Surgery: In cases of hyperfunctioning endocrine organs, such as the thyroid or adrenal glands, surgical removal may be indicated to alleviate hyperthyroidism, Cushing's syndrome, or other endocrinopathies. These procedures can help restore hormonal balance and alleviate symptoms.11,12

Pharmacological Interventions:

Bisphosphonates: Bisphosphonates, such as alendronate and pamidronate, have been explored in the management of fibrous dysplasia. These medications aim to reduce bone pain and improve bone density. However, their long-term efficacy remains a subject of ongoing research.11,12

Gonadotropin-Releasing Hormone (GnRH) Analogues: GnRH analogues, like leuprolide, are employed in the treatment of precocious puberty in MAS. These medications suppress the hormonal signals responsible for early puberty, allowing for more normal pubertal development.11,12

Antithyroid Medications: For MAS patients with hyperthyroidism, antithyroid medications, such as methimazole, may be used to regulate thyroid hormone production and alleviate symptoms.11,12

Supportive Care:

MAS management often involves addressing the complications and comorbidities associated with the syndrome. Supportive care measures may include:

Pain Management: Managing chronic pain associated with fibrous dysplasia is crucial. Non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy, and lifestyle modifications may be recommended.11,12

Endocrine Monitoring: Regular monitoring of endocrine function is essential to manage the hormonal imbalances that often arise in MAS. This involves the use of hormonal replacement therapies or medications to control excessive hormone production.

Dermatologic Care: Routine dermatologic evaluation can help manage café-au-lait spots and address any concerns related to skin pigmentation.11,12

Emerging Therapies:

Research into potential targeted therapies for MAS is ongoing, with a focus on the dysregulated cAMP signaling pathway caused by GNAS mutations. Small molecule inhibitors of cAMP signaling, such as the use of phosphodiesterase (PDE) inhibitors, are being investigated for their potential to mitigate the effects of MAS. Clinical trials and experimental treatments are being explored to assess the safety and efficacy of these novel approaches.11,12

In conclusion, the management of McCune-Albright Syndrome is a multifaceted endeavor that requires the collaboration of various healthcare specialists, including orthopedic surgeons, endocrinologists, dermatologists, and others. The individualized treatment plan for MAS patients should address their specific clinical manifestations, with a focus on alleviating pain, normalizing hormonal imbalances, and enhancing overall quality of life. As research continues to shed light on the molecular mechanisms underlying MAS, the prospect of targeted therapies and more effective interventions holds promise for improving the long-term outcomes of individuals living with this challenging and rare disorder.11,12

CONCLUSIONS

McCune-Albright Syndrome (MAS) stands as a rare and enigmatic disorder characterized by a mosaic pattern of somatic mutations within the GNAS gene, leading to a complex clinical picture encompassing skeletal, cutaneous, and endocrine manifestations. The management of MAS is a complex and multidisciplinary endeavor that necessitates the collaboration of a range of healthcare professionals, ongoing research, and a patient-centered approach. In conclusion, this comprehensive discussion underscores several key insights and takeaways concerning MAS:

1. Diagnosis as the Cornerstone: The diagnostic journey for MAS is fraught with complexity due to the mosaic nature of GNAS mutations, which often results in variable clinical presentations. A high degree of clinical suspicion, supported by radiological, hormonal, and genetic testing, is paramount for early and accurate diagnosis. The process of differential diagnosis, distinguishing MAS from other conditions that share clinical features, is equally challenging.

2. The Clinical Heterogeneity of MAS: MAS is a condition that defies a one-size-fits-all approach. The syndrome exhibits a wide range of clinical manifestations, and the severity of these features can vary significantly among affected individuals. Consequently, the management of MAS must be highly individualized, tailored to the unique needs and challenges presented by each patient.

3. The Surgical and Pharmacological Arsenal: Surgical interventions play a crucial role in addressing skeletal deformities, fractures, and pain resulting from polyostotic fibrous dysplasia. Pharmacological treatments, such as bisphosphonates, GnRH analogues, and antithyroid medications, are employed to alleviate specific clinical manifestations. However, the efficacy and long-term outcomes of some of these interventions remain topics of ongoing research.

4. The Promise of Emerging Therapies: Research into novel, targeted therapies for MAS is an area of growing interest. Small molecule inhibitors aimed at mitigating the dysregulated cAMP signaling pathway, which is central to the pathogenesis of MAS, hold promise for future treatments. These emerging therapies offer hope for more effective and less invasive interventions in the future.

5. The Role of Multidisciplinary Care: MAS demands a multidisciplinary approach, with collaboration among orthopedic surgeons, endocrinologists, dermatologists, geneticists, and other specialists. This holistic approach ensures that all aspects of the condition, from bone health to hormonal regulation, are addressed, offering comprehensive care to patients.

6. A Continuing Need for Research: While significant progress has been made in understanding the genetic basis and clinical management of MAS, many questions remain unanswered. Ongoing research is essential to further unravel the molecular mechanisms underlying MAS, refine diagnostic techniques, and identify more effective therapeutic approaches.

7. Patient-Centered Care: Finally, it is imperative that individuals living with MAS are at the center of their care. This entails not only addressing their clinical needs but also providing the support and resources necessary to improve their quality of life and overall well-being.

In summary, the complexity of McCune-Albright Syndrome necessitates a comprehensive, patient-centered, and multidisciplinary approach to diagnosis and management. The synergy between clinical expertise and ongoing research holds the promise of improving the quality of life for individuals affected by MAS and offering hope for more effective therapies in the future. As the medical community continues to advance its understanding of MAS, the prospect of enhanced diagnosis, treatment, and patient care is on the horizon, offering hope to those living with this rare and challenging condition.

REFERENCES

I. Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis. 2008 May 19;3:12.

II. Turan S, Bastepe M. GNAS Spectrum of Disorders. Curr Osteoporos Rep. 2015 Jun;13(3):146-58.

III. Leet AI, Collins MT. Current approach to fibrous dysplasia of bone and McCune-Albright syndrome. J Child Orthop. 2007 Mar;1(1):3-17.

IV. Belsuzarri TA, Araujo JF, Melro CA, Neves MW, Navarro JN, Brito LG, Pontelli LO, de Abreu Mattos LG, Gonçales TF, Zeviani WM. McCune-Albright syndrome with craniofacial dysplasia: Clinical review and surgical management. Surg Neurol Int. 2016;7(Suppl 6):S165-9.

V. Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, Robey PG, Bianco P, Wientroub S, Collins MT. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res. 2004 Apr;19(4):571-7.

VI. Bercaw-Pratt JL, Moorjani TP, Santos XM, Karaviti L, Dietrich JE. Diagnosis and management of precocious puberty in atypical presentations of McCune-Albright syndrome: a case series review. J Pediatr Adolesc Gynecol. 2012 Feb;25(1):e9-e13.

VII. Shetty S, Varghese RT, Shanthly N, Paul TV. Toxic Thyroid Adenoma in McCune-Albright Syndrome. J Clin Diagn Res. 2014 Feb;8(2):281-2.

VIII. Chakraborty D, Mittal BR, Kashyap R, Manohar K, Bhattacharya A, Bhansali A. Radioiodine treatment in McCune-Albright syndrome with hyperthyroidism. Indian J Endocrinol Metab. 2012 Jul;16(4):654-6.

IX. Chen M, Eugster EA. Central Precocious Puberty: Update on Diagnosis and Treatment. Paediatr Drugs. 2015 Aug;17(4):273-81.

X. Estrada A, Boyce AM, Brillante BA, Guthrie LC, Gafni RI, Collins MT. Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome. Eur J Endocrinol. 2016 Nov;175(5):477-483.

XI. G Buff Passone C, Kuperman H, Cabral de Menezes-Filho H, Spassapan Oliveira Esteves L, Lana Obata Giroto R, Damiani D. Tamoxifen Improves Final Height Prediction in Girls with

McCune-Albright Syndrome: A Long Follow-Up. Horm Res Paediatr. 2015;84(3):184-9.

XII. Benhamou J, Gensburger D, Messiaen C, Chapurlat R. Prognostic Factors From an Epidemiologic Evaluation of Fibrous Dysplasia of Bone in a Modern Cohort: The FRANCEDYS Study. J Bone Miner Res. 2016 Dec;31(12):2167-2172.